Arvind Venkatraman
Vellore, TN, India
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
A novel strategy to target metabolic dependencies in acute myeloid leukemia.
Journal: Cell death & disease
Published: February 03, 2025
Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial.
Journal: Molecular therapy. Oncology
Published: January 06, 2025
Ablation of Wnt signaling in bone marrow stromal cells overcomes microenvironment-mediated drug resistance in acute myeloid leukemia.
Journal: Scientific reports
Published: December 14, 2023
Cystatin F a potential diagnostic biomarker in acute promyelocytic leukemia.
Journal: Annals of hematology
Published: December 12, 2023
Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia.
Journal: Cell transplantation
Published: September 14, 2023
Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India.
Journal: Bone marrow transplantation
Published: August 23, 2022
Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing.
Journal: Annals of hematology
Published: March 14, 2022
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
Journal: Blood advances
Published: May 17, 2021
Mutation Profile in BCR-ABL1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India.
Journal: Hematology/oncology and stem cell therapy
Published: January 07, 2021
JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis.
JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis.
Journal: Annals of hematology
Published: October 21, 2019
A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide.
Journal: Cancer medicine
Published: August 29, 2019
Stromal cells downregulate miR-23a-5p to activate protective autophagy in acute myeloid leukemia.
Journal: Cell death & disease
Published: April 03, 2019
Last Updated: 09/26/2026